A Phase 3 interventional study of Erenumab Dose 1 and Erenumab Dose 2 in Migraine, sponsored by Amgen. Completed at 101 sites in 13 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing erenumab in Migraine Disorders — 3 open to participants now, 4 under way, 1 of them phase 3. erenumab · Migraine Disorders.
Among the 37 studies testing erenumab in Migraine Disorders, this one is the 18th largest by enrollment, is one of 13 that started in 2019, is one of 9 in phase 3, and was the 16th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →3 of the 37 studies testing erenumab in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:
Danish Headache Center · Sites in Denmark
Ages 18+
Danish Headache Center · Sites in Denmark
Ages 18–50
Stanford University
Ages 18+
By country, each count listing its studies:
erenumab: first FDA approval 2018 (AIMOVIG), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 13 started in 2019.
This study's enrollment of 284 is above the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 261 across the 37 interventional studies. Of the 29 that completed or were terminated, 28 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 37 have an industry lead sponsor. The 8 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 167 (68%) have results posted.
24 studies in Migraine Disorders by Amgen: 1 open now, 2 under way, 1 of them phase 3. Of 22 finished, 20 (91%) have results posted.
Among the 24 studies in Migraine Disorders by Amgen, this one is the 13th largest by enrollment of the 23 interventional ones that give a count, is one of 6 that started in 2019, is one of 5 in phase 3, and was the 16th registered.
Amgen’s Migraine Disorders studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 37 studies testing erenumab in Migraine Disorders, from their registry updates:
Among Amgen’s 24 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with chronic migraine. The study hypothesis is that in pediatric participants with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
This study is a phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with chronic migraine. The trial consists of four phases: screening (up to 3 weeks of initial screening and a 4-week prospective baseline phase); the DBTP (24 weeks for Group 1 subjects; 12-weeks for Group 2 subjects) in which participants receive placebo or erenumab dose 1, dose 2 or dose 3 (based on participant's body-weight) via subcutaneous injection once a month; the optional dose level blinded extension phase (40 weeks), in which all participants are assigned to receive dose 1, dose 2 or dose 3 of erenumab; and a 12 weeks safety follow-up phase (16 weeks after the last dose of investigational drug). The study intends to enrol 286 participants (256 adolescents and 30 children).
Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
Drug: Erenumab Dose 1 · Drug: Erenumab Dose 2
Participants will be randomized to one of two doses determined by their body-weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
Drug: Erenumab Dose 2 · Drug: Erenumab Dose 3
Other: Placebo
Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
Also known as: AMG 334, Aimovig®
Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
Also known as: AMG 334, Aimovig®
Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
Also known as: AMG 334, Aimovig®
Placebo matching dose for erenumab dose 1, 2 and 3.
Change From Baseline in MMD to Week 9 Through Week 12 (Month 3) of the DBTP
A migraine day was defined as any calendar day in which the participant developed a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). MMD was defined as the number of migraine days between each monthly IP dose. MMD at baseline was the number of migraine days in the 4-week baseline phase. The least squares mean (LSM) was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment group with scheduled visit. Participants were used as a random effect. As pre-specified in the Statistical Analysis Plan (SAP), only results from adolescents are presented.
Time frame: Baseline to Week 12
Change From Baseline in Monthly Headache Days to Week 9 Through Week 12 (Month 3) of the DBTP
A headache day was defined as any calendar day in which the participant develops a qualified headache (onset, continuation, or recurrence of the headache). Monthly headache days were defined as the number of headache days between each monthly IP dose. Monthly headache days at baseline was the number of headache days in the 4-week baseline phase. LSM was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment with scheduled visit. Participants were used as a random effect. As pre-specified in the SAP, only results from adolescents are presented.
Time frame: Baseline to Week 12
Number of Participants With at Least 50% Reduction in MMD From Baseline to Week 9 Through Week 12 (Month 3) of the DBTP
A migraine day was defined as any calendar day in which the participant developed a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). MMD was defined as the number of migraine days between each monthly IP dose. MMD at baseline was the number of migraine days in the 4-week baseline phase. All participants included in the overall number of participants analyzed contributed to the post-baseline data for this endpoint. As pre-specified in the SAP, only results from adolescents are presented.
Time frame: Baseline to Week 12
Change From Baseline in MMD to the Average of the First 3 Months (Week 1 Through Week 12) of the DBTP
A migraine day was defined as any calendar day in which the participant developed a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). MMD was defined as the number of migraine days between each monthly IP dose. MMD at baseline was the number of migraine days in the 4-week baseline phase. LSM was calculated using a fixed effects analysis of covariance (ANCOVA) model, including terms for treatment group, baseline value as covariate, and stratification factors of region and prior preventive treatment failure. As pre-specified in the SAP, only results from adolescents are presented.
Time frame: Baseline to Week 12
Change From Baseline in Monthly Average Severity of Migraine Attacks to Week 9 Through Week 12 (Month 3) of the DBTP
Severity of qualified migraine headache was measured by using 100 mm Visual Analogue Scale (VAS). Monthly average severity of migraine attack was defined as sum of the severity of each migraine episodes during the migraine attacks between two consecutive monthly IP doses divided by total number of observed migraine episodes during migraine attacks in that monthly interval. 100 mm VAS ranged from 0 to 100 mm, where 0 represents no pain (lowest severity of migraine) and 100 represents worst possible pain (highest severity of migraine). Negative change from baseline indicates an improvement in symptoms. LSM was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment with scheduled visit. Participants were used as a random effect. As pre-specified in the SAP, only results from adolescents are presented.
Time frame: Baseline to Week 12
Change From Baseline in Migraine-related Disability and Productivity as Measured by the Modified Pediatric Migraine Disability Assessment (PedMIDAS) to Week 9 Through Week 12 (Month 3) of the DBTP
Modified PedMIDAS is a 6-item self-administered questionnaire that measures the disability in 2 settings: at school and at home. Modified PedMIDAS score is the sum of missed school days, days when activities at school or home were reduced by at least half due to headaches, and days when other family, social, leisure activities were reduced by at least half due to headaches. Modified PedMIDAS: 0-10: little/none;11-30: mild; 31-50: moderate; \>50; severe; Minimum value 0, maximum value 80, higher scores mean a worse outcome. Negative change from baseline indicates an improvement in symptoms. LSM was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment with scheduled visit. Participants were used as a random effect. As pre-specified in the SAP, only results from adolescents are presented.
Time frame: Baseline to Week 12
A total of 284 participants were enrolled across 12 countries between Sep 2019 and Jan 2026. Participants entered a double-blind treatment phase (DBTP), initially planned for 24 weeks but reduced to 12 weeks following a protocol amendment. Participants in both treatment groups could enter a 40-week dose-level-blinded extension phase (DLBEP). AMG 334 recipients continued the same blinded dose, while placebo recipients were re-randomized 1:1 to AMG 334 dose level 1 or 2 in a double-blind manner.
| Milestone | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 Dose Level 1 (DBTP) | Adolescents - AMG 334 Dose Level 2 (DBTP) | Children - Placebo (DBTP) | Children - AMG 334 Dose Level 1 (DBTP) | Children - AMG 334 Dose Level 2 (DBTP) | Adolescent - AMG 334 Dose Level 1 (DLBEP) | Adolescent - AMG 334 Dose Level 2 (DLBEP) | Children - AMG 334 Dose Level 1 (DLBEP) | Children - AMG 334 Dose Level 2 (DLBEP) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 129 | 65 | 67 | 14 | 5 | 4 | 0 | 0 | 0 | 0 |
| Completed | 124 | 63 | 64 | 13 | 5 | 4 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant request | 2 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason missing | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 Dose Level 1 (DBTP) | Adolescents - AMG 334 Dose Level 2 (DBTP) | Children - Placebo (DBTP) | Children - AMG 334 Dose Level 1 (DBTP) | Children - AMG 334 Dose Level 2 (DBTP) | Adolescent - AMG 334 Dose Level 1 (DLBEP) | Adolescent - AMG 334 Dose Level 2 (DLBEP) | Children - AMG 334 Dose Level 1 (DLBEP) | Children - AMG 334 Dose Level 2 (DLBEP) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 123 | 123 | 12 | 10 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 96 | 96 | 11 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 27 | 27 | 1 | 1 |
| Withdrew: Participant request | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 25 | 1 | 1 |
| Withdrew: Decision by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
A headache day was defined as any calendar day in which the participant develops a qualified headache (onset, continuation, or recurrence of the headache). Monthly headache days were defined as the number of headache days between each monthly IP dose. Monthly headache days at baseline was the number of headache days in the 4-week baseline phase. LSM was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment with scheduled visit. Participants were used as a random effect. As pre-specified in the SAP, only results from adolescents are presented.
| days per month | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) |
|---|---|---|
| Change From Baseline in Monthly Headache Days to Week 9 Through Week 12 (Month 3) of the DBTP | -4.52 ± 0.59 | -5.02 ± 0.58 |
A migraine day was defined as any calendar day in which the participant developed a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). MMD was defined as the number of migraine days between each monthly IP dose. MMD at baseline was the number of migraine days in the 4-week baseline phase. All participants included in the overall number of participants analyzed contributed to the post-baseline data for this endpoint. As pre-specified in the SAP, only results from adolescents are presented.
| participants | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) |
|---|---|---|
| Number of Participants With at Least 50% Reduction in MMD From Baseline to Week 9 Through Week 12 (Month 3) of the DBTP | 38 | 32 |
A migraine day was defined as any calendar day in which the participant developed a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). MMD was defined as the number of migraine days between each monthly IP dose. MMD at baseline was the number of migraine days in the 4-week baseline phase. LSM was calculated using a fixed effects analysis of covariance (ANCOVA) model, including terms for treatment group, baseline value as covariate, and stratification factors of region and prior preventive treatment failure. As pre-specified in the SAP, only results from adolescents are presented.
| days per month | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) |
|---|---|---|
| Change From Baseline in MMD to the Average of the First 3 Months (Week 1 Through Week 12) of the DBTP | -3.53 ± 0.51 | -3.48 ± 0.50 |
Severity of qualified migraine headache was measured by using 100 mm Visual Analogue Scale (VAS). Monthly average severity of migraine attack was defined as sum of the severity of each migraine episodes during the migraine attacks between two consecutive monthly IP doses divided by total number of observed migraine episodes during migraine attacks in that monthly interval. 100 mm VAS ranged from 0 to 100 mm, where 0 represents no pain (lowest severity of migraine) and 100 represents worst possible pain (highest severity of migraine). Negative change from baseline indicates an improvement in symptoms. LSM was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment with scheduled visit. Participants were used as a random effect. As pre-specified in the SAP, only results from adolescents are presented.
| score on a scale | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) |
|---|---|---|
| Change From Baseline in Monthly Average Severity of Migraine Attacks to Week 9 Through Week 12 (Month 3) of the DBTP | -1.67 ± 1.88 | -3.75 ± 1.84 |
Modified PedMIDAS is a 6-item self-administered questionnaire that measures the disability in 2 settings: at school and at home. Modified PedMIDAS score is the sum of missed school days, days when activities at school or home were reduced by at least half due to headaches, and days when other family, social, leisure activities were reduced by at least half due to headaches. Modified PedMIDAS: 0-10: little/none;11-30: mild; 31-50: moderate; \>50; severe; Minimum value 0, maximum value 80, higher scores mean a worse outcome. Negative change from baseline indicates an improvement in symptoms. LSM was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment with scheduled visit. Participants were used as a random effect. As pre-specified in the SAP, only results from adolescents are presented.
| score on a scale | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) |
|---|---|---|
| Change From Baseline in Migraine-related Disability and Productivity as Measured by the Modified Pediatric Migraine Disability Assessment (PedMIDAS) to Week 9 Through Week 12 (Month 3) of the DBTP | -7.53 ± 1.48 | -13.26 ± 1.47 |
A migraine day was defined as any calendar day in which the participant developed a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). MMD was defined as the number of migraine days between each monthly IP dose. MMD at baseline was the number of migraine days in the 4-week baseline phase. The least squares mean (LSM) was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment group with scheduled visit. Participants were used as a random effect. As pre-specified in the Statistical Analysis Plan (SAP), only results from adolescents are presented.
| days per month | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) |
|---|---|---|
| Change From Baseline in MMD to Week 9 Through Week 12 (Month 3) of the DBTP | -4.45 ± 0.63 | -4.53 ± 0.62 |
Collected over Up to Week 12 (for participants enrolled following the protocol amendment) or up to Week 24 (for participants enrolled under the original protocol), followed by 40-weeks DLBEP period, and then 12-weeks safety follow-up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adolescents - Placebo (DBTP) | 0/129 (0%) | 6/129 (4.7%) | 49/129 (38%) |
| Adolescents - AMG 334 (DBTP) | 0/132 (0%) | 4/132 (3%) | 53/132 (40.2%) |
| Children - Placebo (DBTP) | 0/14 (0%) | 1/14 (7.1%) | 8/14 (57.1%) |
| Children - AMG 334 (DBTP) | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| Adolescent - AMG 334 Dose Level 1 (DLBEP) | 0/123 (0%) | 5/123 (4.1%) | 66/123 (53.7%) |
| Adolescent - AMG 334 Dose Level 2 (DLBEP) | 0/123 (0%) | 12/123 (9.8%) | 66/123 (53.7%) |
| Children - AMG 334 Dose Level 1 (DLBEP) | 0/12 (0%) | 3/12 (25%) | 10/12 (83.3%) |
| Children - AMG 334 Dose Level 2 (DLBEP) | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Event | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) | Children - Placebo (DBTP) | Children - AMG 334 (DBTP) | Adolescent - AMG 334 Dose Level 1 (DLBEP) | Adolescent - AMG 334 Dose Level 2 (DLBEP) | Children - AMG 334 Dose Level 1 (DLBEP) | Children - AMG 334 Dose Level 2 (DLBEP) |
|---|---|---|---|---|---|---|---|---|
| Sinusitis bacterialInfections and infestations | 0/129 | 0/132 | 0/14 | 0/9 | 0/123 | 0/123 | 1/12 | 0/10 |
| ObesityMetabolism and nutrition disorders | 0/129 | 0/132 | 0/14 | 0/9 | 0/123 | 0/123 | 1/12 | 0/10 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/129 | 0/132 | 0/14 | 0/9 | 0/123 | 0/123 | 1/12 | 0/10 |
| Upper respiratory tract infectionInfections and infestations | 0/129 | 0/132 | 1/14 | 0/9 | 0/123 | 0/123 | 0/12 | 0/10 |
| MigraineNervous system disorders | 0/129 | 0/132 | 1/14 | 0/9 | 0/123 | 4/123 | 0/12 | 0/10 |
| Status migrainosusNervous system disorders | 2/129 | 0/132 | 0/14 | 0/9 | 0/123 | 1/123 | 0/12 | 0/10 |
| Helicobacter gastritisInfections and infestations | 0/129 | 1/132 | 0/14 | 0/9 | 1/123 | 0/123 | 0/12 | 0/10 |
| AppendicolithGastrointestinal disorders | 0/129 | 0/132 | 0/14 | 0/9 | 0/123 | 1/123 | 0/12 | 0/10 |
| Anaphylactic reactionImmune system disorders | 0/129 | 0/132 | 0/14 | 0/9 | 1/123 | 0/123 | 0/12 | 0/10 |
| Campylobacter colitisInfections and infestations | 0/129 | 0/132 | 0/14 | 0/9 | 0/123 | 1/123 | 0/12 | 0/10 |
| Event | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) | Children - Placebo (DBTP) | Children - AMG 334 (DBTP) | Adolescent - AMG 334 Dose Level 1 (DLBEP) | Adolescent - AMG 334 Dose Level 2 (DLBEP) | Children - AMG 334 Dose Level 1 (DLBEP) | Children - AMG 334 Dose Level 2 (DLBEP) |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 12/129 | 13/132 | 2/14 | 0/9 | 17/123 | 21/123 | 3/12 | 1/10 |
| Upper respiratory tract infectionInfections and infestations | 3/129 | 8/132 | 0/14 | 1/9 | 11/123 | 14/123 | 2/12 | 1/10 |
| InfluenzaInfections and infestations | 2/129 | 3/132 | 1/14 | 0/9 | 6/123 | 6/123 | 2/12 | 1/10 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/129 | 1/132 | 0/14 | 0/9 | 1/123 | 0/123 | 2/12 | 0/10 |
| COVID-19Infections and infestations | 9/129 | 9/132 | 1/14 | 0/9 | 15/123 | 14/123 | 0/12 | 1/10 |
| Injection site reactionGeneral disorders | 0/129 | 2/132 | 0/14 | 1/9 | 1/123 | 1/123 | 0/12 | 0/10 |
| HordeolumInfections and infestations | 0/129 | 1/132 | 0/14 | 1/9 | 0/123 | 0/123 | 0/12 | 0/10 |
| HeadacheNervous system disorders | 0/129 | 4/132 | 0/14 | 1/9 | 4/123 | 2/123 | 1/12 | 0/10 |
| Abdominal pain upperGastrointestinal disorders | 3/129 | 2/132 | 1/14 | 0/9 | 1/123 | 5/123 | 0/12 | 1/10 |
| BronchitisInfections and infestations | 1/129 | 0/132 | 1/14 | 0/9 | 0/123 | 1/123 | 0/12 | 1/10 |
Full analysis set: all participants who were randomized in the trial.
| Age, Continuous(years) | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) | Children - Placebo (DBTP) | Children - AMG 334 (DBTP) | Total |
|---|---|---|---|---|---|
| Mean | 15.36 ± 1.40 | 15.12 ± 1.58 | 9.79 ± 1.37 | 8.78 ± 1.64 | 14.77 ± 2.19 |
| Sex: Female, Male(Participants) | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) | Children - Placebo (DBTP) | Children - AMG 334 (DBTP) | Total |
|---|---|---|---|---|---|
| Female | 103 | 106 | 8 | 4 | 221 |
| Male | 26 | 26 | 6 | 5 | 63 |
| Ethnicity (NIH/OMB)(Participants) | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) | Children - Placebo (DBTP) | Children - AMG 334 (DBTP) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 5 | 0 | 0 | 14 |
| Not Hispanic or Latino | 120 | 127 | 14 | 9 | 270 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) | Children - Placebo (DBTP) | Children - AMG 334 (DBTP) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 22 | 18 | 1 | 0 | 41 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 2 | 0 | 5 |
| White | 98 | 106 | 11 | 9 | 224 |
| More than one race | 2 | 4 | 0 | 0 | 6 |
| Unknown or Not Reported | 5 | 3 | 0 | 0 | 8 |
| Monthly Migraine Days (MMD) During Baseline Phase(days per month) | Adolescents - Placebo (DBTP) | Adolescents - AMG 334 (DBTP) | Children - Placebo (DBTP) | Children - AMG 334 (DBTP) | Total |
|---|---|---|---|---|---|
| Mean | 19.90 ± 5.30 | 19.83 ± 5.88 | 19.62 ± 5.06 | 18.86 ± 5.14 | 19.82 ± 5.54 |
Showing the first 100 of 101 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Sep 2019 to primary completion in Jan 2025, 64 months.
Results were first posted in Oct 2026, 1 year 9 months after primary completion. A results delay was requested in Oct 2025.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 64 months is above that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Erenumab